CORE--ADVANCED TECHNOLOGY LABORATORIES
CORE--ADVANCED TECHNOLOGY LABORATORIES
批准号:
6099319
负责人:
MARK A JACOBSON
金额:
$15.75万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 1999-12-31
关键词:
AIDS AIDS therapy HIV infections antiAIDS agent antibody neutralization test biomarker biomedical facility clinical research cooperative study cytokine drug metabolism human immunodeficiency virus 1 human subject human therapy evaluation immunity immunology neutralizing antibody pathologic process pharmacokinetics pharmacology polymerase chain reaction serology /serodiagnosis virus antigen
中文摘要
所有抗感染药物的临床试验均采用微生物
评估化疗剂的体内活性的测试,
study. 抗逆转录病毒药物的临床试验也需要类似的试验。
这是UCSF ACTU病毒学核心实验室的目标,
已知或怀疑测量体内抗逆转录病毒作用的试验,
可重现,进行已知或疑似体内测量的试验
抗逆转录病毒的效果,以可重复的,快速和准确的方式。
目前,最广泛用于评估体内抗逆转录病毒的测试
影响是血清HIV p24(核心)抗原,和外周血培养
血液单核细胞检测艾滋病病毒 虽然血清中的变化
p24抗原的浓度似乎是抗逆转录病毒的良好量度
逆转录酶抑制剂的作用,白细胞的简单培养
艾滋病毒没有。 因此,ACTG正在向定量文化发展
作为体内抗逆转录病毒作用的另一个标志物,
检测(例如,PCR扩增后测量HIV cDNA或基因组RNA)
正在考虑。 加州大学旧金山分校ACTU核心病毒学实验室已经
自1987年以来进行HIV培养和p24测定,
自1989年以来连续获得p24抗原检测认证,
文化自1990年以来 此外,我们还在一些
未经认证的程序,如细胞的定量微量培养,
血浆,以及HIV cDNA和基因组RNA的PCR定量。 具体
UCSF ACTU核心病毒学实验室的目标是进行HIV培养,
p24抗原定量和ACTU所需的其他病毒学检测
为了以后的测试;通过参加ACTG来保持我们的熟练程度
质量保证计划,并与ACTG在全国范围内合作,
并验证体内抗逆转录病毒作用的其他标志物。
英文摘要
All clinical trials of anti-infective agents have employed microbiologic
tests to assess the in vivo activity of the chemotherapeutic agent under
study. Similar tests are needed for clinical trails of antiretrovirals.
It is the goal of the Virology Core Laboratory of the UCSF ACTU to perform
tests known or suspected of measuring in vivo antiretroviral effect in a
reproducible, perform tests known or suspected of measuring in vivo
antiretroviral effect in a reproducible, rapid and accurate fashion.
Currently the tests most widely used for assessing in vivo antiretroviral
effect are the serum HIV p24 (core) antigen, and culture of peripheral
blood mononuclear cells for HIV. Although changes in the serum
concentration of p24 antigen appear to be a good measure of antiretroviral
effect with reverse transcriptase inhibitors, simple culture of leukocytes
for HIV has not. The ACTG is therefore moving toward quantitative culture
of plasma as another marker of in vivo antiretroviral effect, and other
tests (e.g. measurement of HIV cDNA or genomic RNA after PCR amplification)
are being considered. The UCSF ACTU Core Virology Laboratory has been
performing HIV culture and p24 determination since 1987, and has been
certified continuously for p24 antigen testing since 1989 and for HIV
culture since 1990. In addition, we have experience in some as-yet
uncertified procedures such as quantitative microculture of cells and
plasma, and PCR quantitation of HIV cDNA and genomic RNA. The specific
aims of the UCSF ACTU Core Virology Laboratory are to perform HIV cultures,
p24 antigen quantitation, and other virologic testing as needed for ACTU's
for later testing; to maintain our proficiency by participating in ACTG
quality assurance programs, and to work with the ACTG nationally to develop
and validate other markers of in vivo antiretroviral effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV Epitope Specific T Cell Responses and Control of HIV Replication
-
批准号:7282098
-
项目类别:
-
资助金额:$23.09万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
-
批准号:7336264
-
项目类别:
-
资助金额:$23.11万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
HIV Epitope Specific T Cell Responses and Control of HIV Replication
-
批准号:7417845
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
-
批准号:7489883
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
CMV Immune Response & Long-Term Outcome of CMV Retinitis
-
批准号:6745723
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
CMV Immune Response & Long-Term Outcome of CMV Retinitis
-
批准号:6848025
-
项目类别:
-
资助金额:$25.92万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
THE ROLE OF PROTEIN LOOP FLEXIBILITY IN SUBSTRATE BINDING
-
批准号:7181783
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG 5079: PHYSIOLOGIC TESTOSTERONE
-
批准号:7203030
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS
-
批准号:7203039
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG 5079: Physiologic testosterone
-
批准号:7044942
-
项目类别:
-
资助金额:$0.57万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
A5159: HIV protease inhibitors and calcium channel blockers
-
批准号:7044955
-
项目类别:
-
资助金额:$0.57万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS
-
批准号:7044951
-
项目类别:
-
资助金额:$4.95万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
ACTG 5077: HAART/HIV compartments
-
批准号:7044920
-
项目类别:
-
资助金额:$0.98万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG A5082: Metformin/ Rosiglitazone
-
批准号:7044930
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6467926
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6623575
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6737543
-
项目类别:
-
资助金额:$10.37万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6453039
-
项目类别:
-
资助金额:$13.19万
-
财政年份:2001
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6507450
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2001
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6302657
-
项目类别:
-
资助金额:$34.93万
-
财政年份:2000
-
负责人:MARK A JACOBSON
-
依托单位:
海外基金